Scilex Holding (SCLX) Income from Continuing Operations (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Income from Continuing Operations of 45650000.0 for Q1 2026, down 75.04% year-over-year from 182880491.55 in Q1 2025, and up 0.99% quarter-over-quarter from 46105000.0 in Q4 2025.
Scilex Holding (SCLX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Scilex Holding's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 45650000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 75.04% year-over-year to 45650000.0; the TTM figure through Mar 2026 stood at 393623000.0 (down 428.28% YoY), while the FY2025 annual figure was 374053000.0, down 413.76% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 45650000.0, up from 46105000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 21501000.0 in Q3 2022, with the low at 257820000.0 in Q3 2025.
- The 5-year median for Income from Continuing Operations is 26080000.0 (2025), against an average of 37070882.35.
- Peak annual rise in Income from Continuing Operations reached 7736.6% in 2022, while the deepest fall reached 10688.09% in 2022.
- Scilex Holding's Income from Continuing Operations stood at 17884000.0 in 2022, then dropped by 19.66% to 21400000.0 in 2023, then soared by 69.81% to 6460000.0 in 2024, then tumbled by 613.7% to 46105000.0 in 2025, then grew by 0.99% to 45650000.0 in 2026.
- Business Quant data shows SCLX's Income from Continuing Operations at 45650000.0 in Q1 2026, 46105000.0 in Q4 2025, and 257820000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.51 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 207.96 Mn |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn | -114.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.65 Mn |
| Dec 31, 2025 | -46.11 Mn |
| Sep 30, 2025 | -257.82 Mn |
| Jun 30, 2025 | -44.05 Mn |
| Mar 31, 2025 | -26.08 Mn |
| Dec 31, 2024 | -6.46 Mn |
| Sep 30, 2024 | -4.39 Mn |
| Jun 30, 2024 | -37.58 Mn |
| Mar 31, 2024 | -24.38 Mn |
| Dec 31, 2023 | -21.40 Mn |
| Sep 30, 2023 | -35.53 Mn |
| Jun 30, 2023 | -26.65 Mn |
| Mar 31, 2023 | -30.75 Mn |
| Dec 31, 2022 | -17.88 Mn |
| Sep 30, 2022 | 21.50 Mn |
| Jun 30, 2022 | -17.84 Mn |
| Mar 31, 2022 | -9.14 Mn |
| Dec 31, 2021 | -46.93 Mn |
| Sep 30, 2021 | -281,552.00 |
| Jun 30, 2021 | -165,349.00 |